Cellceutix Enrolls Second Group in Phase 2 Trial of IBD Therapy Brilacidin

Cellceutix Enrolls Second Group in Phase 2 Trial of IBD Therapy Brilacidin
Cellceutix has completed enrolling a second cohort of patients with mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), two forms of inflammatory bowel disease (IBD), in its Phase 2 clinical trial evaluating brilacidin (PMX-30063). Treatment of this group is expected to be complete by the end of February. The open-label, proof-of-concept Phase 2 clinical trial is designed to assess

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *